Phencyclidine model of frontal cortical dysfunction in nonhuman primates

Neuroscientist

Volumn 6, Issue 4, 2000, Pages 263-270

  Jentsch, J David ^a   Taylor, Jane R ^b   Roth, Robert H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Dopamine; Glutamate; NMDA; Prefrontal cortex; Schizophrenia

Indexed keywords

2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; BRAIN MONOAMINE; CLOZAPINE; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

BRAIN DYSFUNCTION; FRONTAL CORTEX; FRONTAL LOBE; NEUROCHEMISTRY; NONHUMAN; PATHOPHYSIOLOGY; PRIMATE; REVIEW; SCHIZOPHRENIA;

EID: 0033862388     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385840000600409     Document Type: Review

References (67)

1. Weinberger DR, Berman KF. Prefrontal function in schizophrenia. Confounds and controversies. Philos Trans R Soc Lond B Biol Sci 1996;351:1495-503.
2. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122:593-624.
3. Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized-tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenia subjects. Proc Natl Acad Sci U S A 1996;93:9235-40.
4. Carpenter WT, Buchanan RW. Medical progress: schizophrenia. N Engl J Med 1994;330:681-90.
5. Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs and schizophrenia: a search for common ground. Schizophr Res 1995;16:87-110.
6. Grace AA, Moore H. Regulation of information flow in the nucleus accumbens: a model for the pathophysiology of schizophrenia. In: Lenzenweger MF, Sworkin RH, editors. Origins and development of schizophrenia: advances in experimental psychopathology. Washington, DC: American Psychological Association; 1998. p. 123-60.
7. O'Donnell P, Grace AA. Dysfunctions in multiple inter-related systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 1998;24:267-83.
8. Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999;353:1425-30.
9. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997;23:437-58.
10. Robbins TW. The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull 1990;16:391-402.
11. Pantelis C, Barnes TR, Nelson HE, Tanner S, Weatherley L, Owen AM, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997;120:1823-43.
12. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992;49:975-82.
13. Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 1998;155:1285-7.
14. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computerized tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-52.
15. Fey ET. The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. J Consult Psychol 1951;15:311-19.
16. Ragland JD, Gur RC, Glahn DC, Censits DM, Smith RJ, Lazarev MG, et al. Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: a positron emission tomography study. Neuropsychol 1998;12:399-413.
17. Schroeder J, Tittel A, Stockert A, Karr M. Memory deficits in subsyndromes of chronic schizophrenia. Schizophr Res 1996;21:19-26.
18. Goldman-Rakic PS. Prefrontal cortical dysfunction in schizophrenia: relevance of working memory. In: Carroll BJ, Barrett JE, editors. Psychopathology and the brain. New York: Raven Press; 1991. p. 1-23.
19. Moore H, West AR, Grace AA. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 1999;46:40-55.
20. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
21. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 1999;20:201-25.
22. Steinpreis RE. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 1996;74:45-55.
23. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. Neuropsychological impairment in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-24.
24. Boyce S, Rupniak NMJ, Steventon MJ, Cook G, Iversen SD. Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav Brain Res 1991;42:115-21.
25. Verma A, Moghaddam B. The role of excitatory amino acids in prefrontal cortex function as assessed by spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 1996;16:373-9.
26. Moghaddam B, Adams B. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist. Science 1998;281:1349-52.
27. Huntley GW, Vickers JC, Morrison JH. Cellular and subcellular localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci 1994;17:536-43.
28. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1987;135:1081-4.
29. Rainey JM, Crowder MK. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 1975;132:1076-8.
30. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997;277:953-5.
31. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacol 1997;17:92-9.
32. Jentsch JD, Roth RH, Redmond DE, Taylor JR. Impaired response inhibition in monkeys and rats after long-term phencyclidine exposure. Int J Neuropsychopharmacol 1998;2:186.
33. Diamond A, Zola-Morgan S, Squire LR. Successful performance by monkeys with lesions of the hippocampal formation on A-B and object retrieval, two tasks that mark developmental changes in human infants. Behav Neurosci 1989;103:526-37.
34. Dias R, Robbins TW, Roberts AC. Primate analog of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci 1996;110:872-86.
35. Divac I. Frontal lobe system and spatial reversal in the rat. Neuropsychologia 1971;11:57-65.
36. Didriksen M. Enduring cognitive deficits in rats after long-term administration of phencyclidine. Soc Neurosci Abstr 1999;25:2154.
37. Prince JA, Yassin MS, Oreland L. Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology 1997;36:1665-78.
38. Butchbach MER, Jentsch JD, Roth RH, Higgins DS. Modulation of oxidative metabolism and glutamate receptor density by subchronic phencyclidine treatment in the rat. Soc Neurosci Abstr 1998;24:489.
39. Wang C, Showalter VM, Hillman GR, Johnson KM. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J Neurosci Res 1999;55:762-9.
40. Meador-Woodruff JH, Haroutunian V, Powchick P, Davidson M, Davis KL, Watson SJ. Abnormal NMDA receptor expression in schizophrenic prefrontal cortex. Abstr Am Coll Neuropsychopharmacol 1997;36:167.
41. Arvanov VL, Wang RY. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 1999;289:1000-6.
42. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-77.
43. Qin ZH, Zhang SP, Weiss B. Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Mol Brain Res 1994;21:293-302.
44. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons of prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-66.
45. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997;24:349-55.
46. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit produced by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-31.
47. Arnsten AFT. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997;11:151-62.
48. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 1999;146:373-90.
49. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia. A review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
50. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997;11:123-31.
51. Jentsch JD, Dazzi L, Chhatwal JP, Verrico CD, Roth RH. Reduced prefrontal cortical dopamine but not acetylcholine release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci Lett 1998;258:175-8.
52. Jentsch JD, Taylor JR, Elsworth JD, Redmond DE, Roth RH. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neurosci 1999;90:823-32.
53. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991;251:947-50.
54. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
55. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
56. Schall U, Catts SV, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, et al. The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. Int J Neuropsychopharmacol 1998;1:19-30.
57. Jentsch JD, Taylor JR, Redmond DE, Elsworth JD, Youngren KD, Roth RH. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 1999;142:78-84.
58. Creese I, Burt DR, Synder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenia drugs. Science 1976;192:481-3.
59. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-4.
60. Roth RH. CNS dopamine autoreceptors: distribution, pharmacology and function. Ann N Y Acad Sci 1984;430:27-34.
61. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990;54:1755-60.
62. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, et al. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 1999;20:404-13.
63. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2-receptors, clozapine occupies D4. Neuropsychopharmacology 1992;7:261-84.
64. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
65. Imperato A, Angelucci L. The effects of clozapine and fluperapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull 1989;25:383-8.
66. Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997;338:R3-7.
67. Hertel P, Fagerqvist M, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha-2 adrenoceptor blockade. Science 1999;286:105-7.